RS

Rumi Sarma

Active Director Director DIN 08367455
DIN 08367455 First appointment Feb 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2019
Shareholding value •••• Premium profile

About Rumi Sarma

Data last updated:

Rumi Sarma is a Director at Ollberry Lifesciences Private Limited (since 2019). The company operates in Pharma. Ollberry Lifesciences Private Limited reported revenue of ₹82.7 Lakh (FY 2025).

DIN 08367455
Primary Designation Director
Industry Pharma
First Appointment 19 Feb 2019
Oldest Company Age 7 yrs
Largest company Ollberry Lifesciences Private Limited · ₹82.7 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director19 Feb 20192019₹82.7 Lakh (FY 2025)Active

Board colleagues of Rumi Sarma

NameDINCompanyDesignation
Sushanta Paul09523666Ollberry Lifesciences Private LimitedDirector

Directorship timeline

Open interactive timeline →
Ollberry Lifesciences Private Limited
Premium access

Shareholding and investment profile for Rumi Sarma

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rumi Sarma

Rumi Sarma currently holds 1 directorship: Ollberry Lifesciences Private Limited (Director, since 19 Feb 2019, revenue ₹82.7 Lakh (FY 2025)).

Rumi Sarma was first appointed on 19 Feb 2019 as Director at Ollberry Lifesciences Private Limited.

The current boards of Rumi Sarma's companies include Sushanta Paul (Ollberry Lifesciences Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available